KEY DETAILS
Gizmodo reports that in two trials, Eli Lilly's experimental drug retatrutide significantly reduced sleep apnea symptoms versus placebo.
A finance.yahoo.com item on Counsel Health's weight management program is labeled as a paid press release from Business Wire.
In a rat study reported by News-Medical, semaglutide changed gut bacteria in ways that food restriction alone did not fully reproduce.
The Independent reports on an August paper from Harvard and Copenhagen researchers warning that GLP-1 users risk eating too little protein and fiber.
News-Medical reports a review naming gallbladder and biliary disease as the adverse effect most consistently linked to GLP-1 drugs.
Gizmodo reported on October 26 that two trials, published the previous week in the New England Journal of Medicine, found Eli Lilly's experimental drug retatrutide significantly reduced obstructive sleep apnea symptoms compared with placebo. There is more to the day than one drug. According to News-Medical, a review in the Journal of Internal Medicine names gallbladder and biliary disease as the adverse effect most consistently linked to GLP-1 receptor agonists.
Gizmodo reports that Eli Lilly ran the two trials within its larger phase III studies of retatrutide, one in people with type 2 diabetes and obesity and the other in people with obesity but not diabetes, with roughly 700 participants in total. The next detail is the one many readers may look for first. According to Gizmodo, more than half of retatrutide users in one trial had their sleep apnea go into remission or drop to mild. Gizmodo adds that the benefit was smaller, though still significant, for people with both obesity and type 2 diabetes. The next item calls for a label more than a summary.
A finance.yahoo.com page about Counsel Health's weight management program carries a notice that it is a paid press release, distributed by Business Wire. We treat paid releases as advertising rather than news, so we are not repeating its claims here. The next story needs a little care in how it is read.
News-Medical reports that the study, published in Comprehensive Physiology, compared rats given semaglutide with pair-fed rats that received the same amount and kind of food. This part is worth reading slowly. According to News-Medical, the overall makeup of gut bacteria differed between the semaglutide and pair-fed groups in both male and female rats. News-Medical notes that the findings do not establish whether these changes are good or bad for health. The article also says more research is needed to learn whether the changes happen in people receiving semaglutide.
Nutrition is the next subject. The Independent reports on a paper by researchers at the Harvard T.H. Chan School of Public Health and the University of Copenhagen that was published in August, so it is not new. The paper warns that people who cut back sharply on food while taking GLP-1 drugs risk getting too little protein and fiber. It also says low fiber intake can make stomach problems such as bloating and constipation worse.
Safety is the last subject of the day. News-Medical reports that the review cites a meta-analysis of 76 randomized trials that found a 37% relative increase in gallbladder or biliary disease. One distinction in this review is worth keeping in mind. According to News-Medical, the review says a causal link has not been established for the other serious adverse events it examined, including thyroid cancer and acute pancreatitis. News-Medical adds that the review stresses that, because these events are rare, even large relative increases may mean small absolute increases for people at low baseline risk.
Each of these stories carries more detail than fits in one edition. The full articles are at the outlets linked here, including Gizmodo and The Independent, along with both News-Medical pieces.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.